New drug targets Hard-to-Treat cancers with BRCA2 or PALB2 mutations
NCT ID NCT04890613
First seen May 01, 2026 · Last updated May 15, 2026 · Updated 3 times
Summary
This study tests an experimental drug called CX-5461 in people with advanced solid tumors (like pancreatic, prostate, breast, or ovarian cancer) that have specific gene changes in BRCA2 or PALB2. The goal is to find a safe dose and see if the drug can shrink tumors or slow their growth. About 52 participants will receive the drug through an IV twice per month.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre hospitalier de l'Université de Montréal (CHUM)
RECRUITINGMontreal, Quebec, H2X 0C2, Canada
Contact
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
-
H. Lee Moffitt Cancer Center and Research Institute Hospital
RECRUITINGTampa, Florida, 33612-9497, United States
Contact
-
Memorial Sloan-Kettering Cancer Center
WITHDRAWNNew York, New York, 10065, United States
-
Ohio State University-James Cancer Hospital and Solove Research Institute
RECRUITINGColumbus, Ohio, 43202, United States
Contact
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 1X6, Canada
Contact
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact
-
University of California, Los Angeles
RECRUITINGSanta Monica, California, 90404, United States
Contact
Conditions
Explore the condition pages connected to this study.